---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-098367"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2026-08-18T20:30:26+00:00"
generated_at: "2026-08-18T20:32:25.274546+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AbbVie completes $10B senior notes offering to fund Apogee acquisition

## Summary
- Issued $10.0B aggregate principal across 9 tranches: floating rate notes due 2028 and fixed-rate notes from 4.500% due 2028 to 6.100% due 2066.
- Net proceeds to fund cash consideration for Apogee Therapeutics acquisition and related fees; remainder for general corporate purposes.
- Special mandatory redemption at 101% of principal if Apogee deal terminates before closing (excludes 2056 and 2066 notes).
- Notes are unsecured, unsubordinated, rank equally with existing debt; make-whole redemption provisions apply to fixed-rate notes.
- Offering completed August 18, 2026; supplemental indenture No. 13 filed with trustee U.S. Bank Trust Company.

## SEC filing metadata
- accession: 0001104659-26-098367
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2026-08-18T20:30:26+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000110465926098367/0001104659-26-098367-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000110465926098367/tm2623337d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-098367
- JSON: https://secwatch.observer/filing/0001104659-26-098367.json
- Plain text: https://secwatch.observer/filing/0001104659-26-098367.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.